Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Open Medicine

formerly Central European Journal of Medicine

Editor-in-Chief: Darzynkiewicz, Zbigniew

IMPACT FACTOR 2018: 1.221

CiteScore 2018: 1.01

SCImago Journal Rank (SJR) 2018: 0.329
Source Normalized Impact per Paper (SNIP) 2018: 0.479

ICV 2017: 152.94

Open Access
See all formats and pricing
More options …
Volume 9, Issue 2


Volume 10 (2015)

Adverse reaction of a combined treatment for unresectable liver cancer

Jianjun Ren
  • Department of General Surgery, Affiliated Hospital of Inner Mongolia Medical University, Huhhot, 010050, P.R.China
  • Biotech Pharmaceutical Co., Ltd, Peking, 100176, P.R.China
  • Email
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Tao Jiang
  • Department of General Surgery, Affiliated Hospital of Inner Mongolia medical university, Huhhot, 010050, P.R.China
  • Email
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Rui Peng
  • Department of General Surgery, Affiliated Hospital of Inner Mongolia Medical University, Huhhot, 010050, P.R.China
  • Biotech Pharmaceutical Co., Ltd, Peking, 100176, P.R.China
  • Email
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
Published Online: 2014-02-13 | DOI: https://doi.org/10.2478/s11536-012-0150-5


To investigate the adverse reactions of transcatheter arterial chemoembolization (TACE) combined with trastuzumab in the treatment of unresectable live cancer, 85 unresectable liver cancer patients were treated with 35 mg epirubicin, with lipiodol and gelatin sponge granule as the embolic agent, and trastuzumab (4mg/kg) was administered intravenously. All the adverse reactions were investigated by blood routine examination and the checking of liver, renal and thyroid functions on the postoperative 2nd and 30th day. No patients died of direct medication. The main adverse reactions included haematological toxicity, liver function lesion and postoperative syndromes such as nausea, vomiting, fever and liver area aching. Two days after the treatment, the amount of the serum total bilirubin (TB) and white blood cell (WBC) increased dramatically, while platelet (PLT) changed a little, and creatinine (Cr) and blood urea nitrogen (BUN) did not change at all. Thirty days after the treatment, blood routine, liver and renal functions were examined, demonstrating that the liver function remained unchanged, PLT decreased apparently, WBC was lower, and Cr and BUN changed slightly compared to those before the treatment. The combined treatment is safe for unresectable liver cancer and thus can be used as a routine intervention method.

Keywords: Adverse effect; Hepatoma cell; Radioimmunotherapy; Transcatheter arterial chemoembolization; Trastuzumab

  • [1] Namboodiri A.M., Pandey J.P., Differential inhibition of trastuzumab- and cetuximab-induced cytotoxicity of cancer cells by immunoglobulin G1 expressing different GM allotypes, Clin. Exp. Immunol., 2011, 166, 361–365 http://dx.doi.org/10.1111/j.1365-2249.2011.04477.xCrossrefWeb of ScienceGoogle Scholar

  • [2] Kostyal D., Welt R.S., Danko J., Shay T., Lanning C., Horton K., et al., Trastuzumab and lapatinib modulation of HER2 tyrosine/threonine phosphorylation and cell signaling, Med. Oncol., 2012, 29, 1486–1494 http://dx.doi.org/10.1007/s12032-011-0025-7Web of ScienceCrossrefGoogle Scholar

  • [3] Sawaki M., Mukai H., Tokudome N., Nakayama T., Taira N., Mizuno T., et al., Safety of adjuvant trastuzumab for HER-2-overexpressing elderly breast cancer patients: a multicenter cohort study, Breast Cancer, 2012, 19, 253–258 http://dx.doi.org/10.1007/s12282-011-0270-9CrossrefGoogle Scholar

  • [4] Abe H., Umeda T., Kawai Y., Tanaka M., Mori T., Cho H., et al., [Adjuvant trastuzumab can be infused safely over 30 minutes], Gan To Kagaku Ryoho, 2010, 37, 1887–1891 Google Scholar

  • [5] Fujita T., Doihara H., Kawasaki K., Takabatake D., Takahashi H., Washio K., et al., PTEN activity could be a predictive marker of trastuzumab efficacy in the treatment of ErbB2-overexpressing breast cancer, Br. J. Cancer, 2006, 94, 247–252 http://dx.doi.org/10.1038/sj.bjc.6602926CrossrefGoogle Scholar

  • [6] Perez E.A., Jenkins R.B., Dueck A.C., Wiktor A.E., Bedroske P.P., Anderson S.K., et al., C-MYC alterations and association with patient outcome in early-stage HER2-positive breast cancer from the north central cancer treatment group N9831 adjuvant trastuzumab trial, J. Clin. Oncol., 2011, 29, 651–659 http://dx.doi.org/10.1200/JCO.2010.30.2125CrossrefGoogle Scholar

  • [7] Esteva F.J., Guo H., Zhang S., Santa-Maria C., Stone S., Lanchbury J.S., et al., PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer, Am. J. Pathol., 2010, 177, 1647–1656 http://dx.doi.org/10.2353/ajpath.2010.090885Web of ScienceCrossrefGoogle Scholar

  • [8] Todeschini P., Cocco E., Bellone S., Varughese J., Lin K., Carrara L., et al., Her2/neu extracellular domain shedding in uterine serous carcinoma: implications for immunotherapy with trastuzumab, Br. J. Cancer, 2011, 105, 1176–1182 http://dx.doi.org/10.1038/bjc.2011.369CrossrefGoogle Scholar

  • [9] Nagahisa Y., Imai S., Yamaguchi K., Okabe M., Tsuruta A., Kawamoto K., et al., [A case of liver metastasis of breast cancer responding to trastuzumab plus weekly paclitaxel chemotherapy maintaining CR for 30 months], Gan To Kagaku Ryoho, 2007, 34, 1501–1503 Google Scholar

  • [10] Horiguchi J., Oyama T., Takata D., Rokutanda N., Nagaoka R., Odawara H., et al., Pathological complete response and prognosis in patients receiving neoadjuvant paclitaxel and trastuzumab with and without anthracyclines for stage II and III, HER2-positive operable breast cancer: a single-institute experience, Anticancer Res., 2011, 31, 3041–3046 Google Scholar

  • [11] Takahashi T., Kochi M., Kanamori N., Kaiga T., Funada T., Fujii M., et al., [Complete remission with FLEP chemotherapy for multiple liver metastasis from alpha-fetoprotein-producing gastric cancer-report of a case], Gan To Kagaku Ryoho, 2009, 36, 1885–1888 Google Scholar

  • [12] Yao Y., [Effects of Feiji decoction for soothing the liver combined with psychotherapy on quality of life in primary lung cancer patients], Zhongguo Fei Ai Za Zhi, 2012, 15, 27–33 Google Scholar

  • [13] Tada A., Ogawa M., Inagaki J., Horikoshi N., Inoue K., Yamazaki H., et al., [Arterial infusion of combination chemotherapy consisting of adriamycin and mitomycin C for liver metastases of breast cancer], Gan To Kagaku Ryoho, 1986, 13, 70–74 PubMedGoogle Scholar

  • [14] Osako T., Ito Y., Takahashi S., Tokudome N., Iwase T., Hatake K., Efficacy and safety of trastuzumab plus capecitabine in heavily pretreated patients with HER2-positive metastatic breast cancer, Cancer Chemother. Pharmacol., 2008, 62, 159–164 http://dx.doi.org/10.1007/s00280-007-0586-5Web of ScienceCrossrefGoogle Scholar

  • [15] Kimura M., Tominaga T., Outstanding problems with response evaluation criteria in solid tumors (RECIST) in breast cancer, Breast Cancer, 2002, 9, 153–159 http://dx.doi.org/10.1007/BF02967580CrossrefGoogle Scholar

  • [16] Pectasides D., Pectasides E., Maintenance or consolidation therapy in advanced ovarian cancer, Oncology, 2006, 70, 315–324 http://dx.doi.org/10.1159/000097943CrossrefGoogle Scholar

  • [17] Zak Y., Rhoads K.F., Visser B.C., Predictors of surgical intervention for hepatocellular carcinoma: race, socioeconomic status, and hospital type, Arch. Surg., 2011, 146, 778–784 http://dx.doi.org/10.1001/archsurg.2011.37CrossrefGoogle Scholar

  • [18] Li B., Yu J., Wang L., Li C., Zhou T., Zhai L., Xing L., Study of local three-dimensional conformal radiotherapy combined with transcatheter arterial chemoembolization for patients with stage III hepatocellular carcinoma, Am. J. Clin. Oncol., 2003, 26, e92–99 CrossrefGoogle Scholar

  • [19] Sahara S., Kawai N., Sato M., Tanaka T., Ikoma A., Nakata K., et al., Prospective Evaluation of Transcatheter Arterial Chemoembolization (TACE) with Multiple Anti-Cancer Drugs (Epirubicin, Cisplatin, Mitomycin C, 5-Fluorouracil) Compared with TACE with Epirubicin for Treatment of Hepatocellular Carcinoma, Cardiovasc. Intervent. Radiol., 2012, doi: 10.1007/s00270-012-0352-x CrossrefGoogle Scholar

  • [20] Chen S., Li B., Xie H., Xu L., Niu G., Fan K., et al., Phase I clinical trial of targeted therapy using 131I-Hepama-1 mAb in patients with hepatocellular carcinoma, Cancer Biother. Radiopharm., 2004, 19, 589–600 http://dx.doi.org/10.1089/cbr.2004.19.589CrossrefGoogle Scholar

  • [21] Wang S.E., Xiang B., Guix M., Olivares M.G., Parker J., Chung C.H., et al., Transforming growth factor beta engages TACE and ErbB3 to activate phosphatidylinositol-3 kinase/Akt in ErbB2-overexpressing breast cancer and desensitizes cells to trastuzumab, Mol. Cell Biol., 2008, 28, 5605–5620 http://dx.doi.org/10.1128/MCB.00787-08Web of ScienceCrossrefGoogle Scholar

  • [22] Yamaguchi K., Chijiiwa K., Torato N., Kinoshita M., Tanaka M., Ki-ras codon 12 point and P53 mutations: a molecular examination of the main tumor, liver, portal vein, peripheral arterial blood and para-aortic lymph node in pancreatic cancer, Am. J. Gastroenterol., 2000, 95, 1939–1945 http://dx.doi.org/10.1111/j.1572-0241.2000.02081.xCrossrefGoogle Scholar

  • [23] Le Brun-Ly V., Martin J., Venat-Bouvet L., Darodes N., Labourey J.L., Genet D., et al., Cardiac toxicity with capecitabine, vinorelbine and trastuzumab therapy: case report and review of fluoropyrimidinerelated cardiotoxicity, Oncology, 2009, 76, 322–325 CrossrefGoogle Scholar

  • [24] Ritter C.O., Wartenberg M., Mottok A., Steger U., Goltz J.P., Hahn D., et al., Spontaneous liver rupture after treatment with drug-eluting beads, Cardiovasc. Intervent. Radiol., 2012, 35, 198–202 http://dx.doi.org/10.1007/s00270-011-0145-7CrossrefGoogle Scholar

  • [25] Fromigue J., De Baere T., Baudin E., Dromain C., Leboulleux S., Schlumberger M., Chemoembolization for liver metastases from medullary thyroid carcinoma, J. Clin. Endocrinol. Metab., 2006, 91, 2496–2499 http://dx.doi.org/10.1210/jc.2005-2401CrossrefGoogle Scholar

  • [26] Ruszniewski P., O’Toole D., Ablative therapies for liver metastases of gastroenteropancreatic endocrine tumors, Neuroendocrinology, 2004, 80(Suppl 1), 74–78 http://dx.doi.org/10.1159/000080746CrossrefGoogle Scholar

  • [27] Tu C.M., Chu K.M., Yang S.P., Cheng S.M., Wang W.B., Trastuzumab (Herceptin)-associated cardiomyopathy presented as new onset of complete left bundle-branch block mimicking acute coronary syndrome: a case report and literature review, Am. J. Emerg. Med., 2009, 27, e901–903 Google Scholar

  • [28] Yan X., Morgan J.P., Neuregulin1 as novel therapy for heart failure, Curr. Pharm. Des., 2011, 17, 1808–1817 http://dx.doi.org/10.2174/138161211796391010CrossrefGoogle Scholar

  • [29] Peltier M., Houpe D., Cohen-Solal A., Beguin M., Levy F., Tribouilloy C., Treatment practices in heart failure with preserved left ventricular ejection fraction: a prospective observational study, Int. J. Cardiol., 2007, 118, 363–369 http://dx.doi.org/10.1016/j.ijcard.2006.07.033CrossrefGoogle Scholar

About the article

Published Online: 2014-02-13

Published in Print: 2014-04-01

Citation Information: Open Medicine, Volume 9, Issue 2, Pages 272–278, ISSN (Online) 2391-5463, DOI: https://doi.org/10.2478/s11536-012-0150-5.

Export Citation

© 2014 Versita Warsaw. This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License. BY-NC-ND 3.0

Comments (0)

Please log in or register to comment.
Log in